{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:45Z","timestamp":1791920085355,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.neulet.2020.135222","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T02:32:13Z","timestamp":1593484333000},"page":"135222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's disease"],"prefix":"10.1016","volume":"735","author":[{"given":"Anup","family":"Masih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol Kumar","family":"Agnihotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeena","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Kumar","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Raj","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-0502","authenticated-orcid":false,"given":"Udaya Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2020.135222_bib0005","first-page":"1","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neulet.2020.135222_bib0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.neulet.2020.135222_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neulet.2020.135222_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neulet.2020.135222_bib0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.neulet.2020.135222_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","article-title":"Adenosine A2A receptors in Parkinson\u2019s disease treatment","volume":"4","author":"Cie\u015blak","year":"2008","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neulet.2020.135222_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11302-005-0649-1","article-title":"Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade","volume":"1","author":"Cunha","year":"2005","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neulet.2020.135222_bib0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A2A receptor antagonist treatment of Parkinson\u2019s disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2020.135222_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A2A receptor antagonists in Parkinson\u2019s disease","volume":"105","author":"Xu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2020.135222_bib0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.07.004","article-title":"Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson\u2019s disease","volume":"132","author":"Armentero","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2020.135222_bib0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejmech.2017.09.035","article-title":"1,3,5-Triazines: a promising scaffold for anticancer drugs development","volume":"142","author":"Cascioferro","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neulet.2020.135222_bib0060","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41598-017-05934-5","article-title":"Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase \/631\/92\/436\/2387 \/692\/700\/155 article","volume":"7","author":"Srivastava","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neulet.2020.135222_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.13695","article-title":"Potent antibacterial activity of dihydydropyrimidine-1,3,5-triazines via inhibition of DNA gyrase and antifungal activity with favourable metabolic profile","author":"Masih","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.neulet.2020.135222_bib0070","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.bmcl.2014.05.103","article-title":"Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate","volume":"24","author":"Singh","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2020.135222_bib0075","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00044-010-9446-7","article-title":"Synthesis and antibacterial evaluation of series of novel tri-substituted-s-triazine derivatives","volume":"20","author":"Singh","year":"2011","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.neulet.2020.135222_bib0080","doi-asserted-by":"crossref","DOI":"10.1186\/2193-9616-1-3","article-title":"Hybrid phenylthiazole and 1,3,5-triazine target cytosolic leucyl-tRNA synthetase for antifungal action as revealed by molecular docking studies","volume":"1","author":"Singh","year":"2013","journal-title":"In Silico Pharmacol."},{"key":"10.1016\/j.neulet.2020.135222_bib0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.exppara.2011.12.014","article-title":"Antimalarial evaluation and docking studies of hybrid phenylthiazolyl-1,3,5-triazine derivatives: a novel and potential antifolate lead for Pf-DHFR-TS inhibition","volume":"130","author":"Gahtori","year":"2012","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.neulet.2020.135222_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/jhet.3955","article-title":"Microwave assisted synthesis, docking and antimalarial evaluation of hybrid PABA-substituted 1,3,5-triazine derivatives","author":"Adhikari","year":"2020","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.neulet.2020.135222_bib0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/cbdd.12490","article-title":"Synthesis, docking, in vitro and in vivo antimalarial activity of hybrid 4-aminoquinoline-1,3,5-triazine derivatives against wild and mutant malaria parasites","volume":"86","author":"Bhat","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.neulet.2020.135222_bib0100","doi-asserted-by":"crossref","first-page":"88710","DOI":"10.1039\/C5RA09250G","article-title":"Pharmacological evaluation of hybrid thiazolidin-4-one-1,3,5-triazines for NF-\u03baB, biofilm and CFTR activity","volume":"5","author":"Srivastava","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.neulet.2020.135222_bib0105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.str.2011.06.014","article-title":"Structure of the adenosine A 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine","volume":"19","author":"Dor\u00e9","year":"2011","journal-title":"Structure."},{"key":"10.1016\/j.neulet.2020.135222_bib0110","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/cmdc.201300474","article-title":"Binding kinetics of ZM241385 derivatives at the human adenosine A 2A receptor","volume":"9","author":"Guo","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neulet.2020.135222_bib0115","article-title":"Static magnetic field exposure reproduces cellular effects of the Parkinson\u2019s disease drug candidate ZM241385","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2020.135222_bib0120","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2174\/1389557518666180423113051","article-title":"A2A adenosine receptor antagonists as therapeutic candidates: are they still an interesting challenge?","volume":"18","author":"Cacciari","year":"2018","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.neulet.2020.135222_bib0125","first-page":"S1","article-title":"Abstracts of the 21st international congress of Parkinson\u2019s disease and movement disorders","volume":"32","author":"K. K","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2020.135222_bib0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/mdc3.12187","article-title":"Adenosine 2A receptor antagonists for the treatment of motor symptoms in Parkinson\u2019s disease","volume":"2","author":"Pourcher","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neulet.2020.135222_bib0135","first-page":"254","article-title":"Synthesis, antimicrobial and anticancer thiadiazole-2-Amines","volume":"10","author":"Upadhyay","year":"2017","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/j.neulet.2020.135222_bib0140","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm021053p","article-title":"A comparison of physiochemical property profiles of development and marketed oral drugs","volume":"46","author":"Wenlock","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neulet.2020.135222_bib0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/17460441.2017.1344210","article-title":"Lipophilicity and biomimetic properties to support drug discovery","volume":"12","author":"Tsopelas","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neulet.2020.135222_bib0150","first-page":"148","article-title":"Evaluation of blockbuster drugs under the rule-of-five","volume":"65","author":"Gim\u00e9nez","year":"2010","journal-title":"Pharmazie."},{"key":"10.1016\/j.neulet.2020.135222_bib0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2012","journal-title":"Curr. Comput. Aided-Drug Des."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020304924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020304924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:36:20Z","timestamp":1759610180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394020304924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"alternative-id":["S0304394020304924"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2020.135222","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2020.135222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"135222"}}